Incorporating Equity into Health Technology Assessment: Recommendations from Two Expert Roundtables

Author(s)

Chapman R1, Onukwugha E2, Swenor B3, Son Rigby C4, Diaby K5, Spangler J1, Bright J1
1Innovation and Value Initiative, Alexandria, VA, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Johns Hopkins University, Baltimore, MD, USA, 4Global Genes, Aliso Viejo, CA, USA, 5Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA

OBJECTIVES: Identify best practices to ensure health equity is integrated into health technology assessment (HTA).

METHODS: In December 2022 and January 2023, the Innovation and Value Initiative (IVI) convened two virtual roundtables including discussants representing lived experience, patient advocacy organizations, researchers, payers, clinicians, and industry. Drawing from their expertise, review of published literature, and previous key informant interviews, the roundtables identified best practices within the context of domains essential to equity in HTA, including: “power, people and processes” (addressing power imbalances in HTA), “methods to measure and address equity impacts,” “data, inputs and infrastructure,” and “communication of HTA.”

RESULTS: A recurring focus was the need for reframing power and representative participation in HTA, and demand for solutions and accountability for change in processes and methods used. Specific emerging themes included:

  • Patient/caregiver expertise and lived experience must be considered on par with other expertise, with co-investigator roles prioritized for people affected by HTA.
  • Transparency, inclusiveness, and accountability are essential for meaningful change in HTA.
  • Researchers and users of HTA should prioritize qualitative and mixed methods where appropriate.
  • Data and analyses should include elements identified as important by patients and reflect perspectives of marginalized patient communities.
  • HTA must incorporate appropriate methods to advance equity that are understandable and accessible to multiple stakeholders.
  • HTA models should highlight data and infrastructure gaps and prioritize research questions that advance equity rather than “building models to data.”

CONCLUSIONS: The roundtables identified best practices, grouped into 1) near-term actions; 2) actions requiring further exploration, testing or development; and 3) up- and down-stream actions requiring leadership and resources that exist outside HTA. Near-term actions focus more on process, power, and accountability measures, as well as testing existing methods and approaches. However, wider attention to stakeholder roles and collaborative responsibilities of researchers and policy makers is needed for change.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

HTA17

Topic

Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Health Disparities & Equity, Value Frameworks & Dossier Format

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×